Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma

^aFrom the Department of Radiology and Biomedical Imaging (E.G.), University of California San Francisco, San Francisco, California
^bDepartment of Radiology (E.F., R.Y.H.), Brigham and Women’s Hospital, Boston, Massachusetts
^cMassachusetts Institute of Technology (K.C.), Cambridge, Massachusetts
^dDepartment of Diagnostic Imaging (H.X.B.), Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island
^eArtificial Intelligence in Medicine Program (H.J.A.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
^fDepartments of Radiation Oncology and Radiology (H.J.A.), Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
^gDepartment of Computer Science (M.V.), Université de Sherbrooke, Sherbrooke, Quebec, Canada
^hCenter for Neuro Oncology (D.A.R.), Dana-Farber Cancer Institute, Boston, Massachusetts

Please address correspondence to Raymond Y. Huang, MD, PhD, Department of Radiology, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115; e-mail: ryhuang{at}bwh.harvard.edu; @LizzRad